Phase III Study of sacituzumab govitecan (IMMU-132) Versus Treatment of Physicians Choice (TPC) in Hormonal Receptor Positive (HR+) HER2 Negative Metastatic Breast Cancer (MBC) who have failed at least one prior line of chemotherapy (IMMU-132-09)

Brief description of study

The main purpose of this study is to determine whether treatment with sacituzumab govitecan could provide a better response and improve survival (the amount of time you live without your cancer growing) for patients who have received at least 2 but no more than 4 prior treatments for metastatic breast cancer when co pared to a choice of one of 4 treat ents for metastatic breast cancer. Information on overall safety, clinical benefit and quality of life, and other basic information and supporting data, will also be collected in this study.


Clinical Study Identifier: s18-01628
ClinicalTrials.gov Identifier: NCT03901339


If you are registered as a volunteer, please login to the dashboard to send referrals.